Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68788-8362

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-8362). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed-release Cap Usp 40mg (2c233b3f 83de 40c4 9f1d 81f901f89459 00)

Label for Duloxetine Delayed-Release Capsule USP 40mg, generic for Cymbalta, containing 44.9mg Duloxetine HCl equivalent to 40mg Duloxetine per capsule. Manufacturer listed as Breckenridge Pharmaceuticals, Inc., Boca Raton, FL. Label includes storage instructions, warnings, a barcode, and a bilingual yellow section for patient dosage directions in English and Spanish. Multiple placeholder fields for lot number, batch number, expiration date, and product number appear unused.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, the active ingredient in Duloxetine Delayed-Release capsules. The diagram shows the molecular arrangement including a naphthalene group, a thiophene ring, and an amine hydrochloride group.*

FDA Label Image

Figure 1 (Duloxetine 02)

Line graph depicting the proportion of patients with relapse over time (days) from randomization, comparing placebo and duloxetine delayed-release capsules. The x-axis represents time in days, and the y-axis shows the proportion of patients experiencing relapse, with the duloxetine group showing a lower relapse proportion compared to placebo across the study period.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve graph depicting the proportion of patients with relapse over time in days from randomization, comparing placebo and duloxetine delayed-release capsules. The graph shows cumulative relapse rates with placebo having a higher proportion compared to duloxetine, across a timeline up to approximately 275 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the relationship between percent improvement in pain from baseline (x-axis) and percentage of patients improved (y-axis) for Duloxetine delayed-release capsules. Four lines compare Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, illustrating differences in patient response rates across varying levels of pain improvement.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline. It compares data for Duloxetine 60 mg taken twice daily (BID), Duloxetine 60 mg taken once daily (QD), and placebo groups. The graph shows trends of patient improvement across varying levels of pain improvement.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine Delayed-Release 60 mg taken twice daily, once daily, and placebo groups in a clinical study on pain improvement.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Four lines represent different treatments: Duloxetine (DUL) 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo. The graph illustrates the distribution of patient improvement percentages for each treatment group.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved across different levels of percent improvement in pain from baseline, showing two groups: Placebo and Duloxetine (DUL) 60/120 mg once daily. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved.*

FDA Label Image

Figure 9 (Duloxetine 09)

Line graph depicting the percentage of patients improved against percent improvement in pain from baseline (BOCF). It compares two groups: Placebo and Duloxetine (60 mg once daily), showing their relative performance over a range of pain improvement percentages.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing percentage improvement in pain from baseline (BOCF) to the percentage of patients improved for placebo versus DULO60/120 mg once daily. The graph shows two curves representing patient response rates over increasing categories of pain improvement percentage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.